study on the efficacy of bharangimoola arka (herbal nebulization followed by bharangi nagara kalka internally(medicine paste) as naimittika rasayana (rejuvenation medicine) in tamaka shvasa vis a viS asthma

Open Label Single Arm Randomized Sudy On Efficacy Of Bharangimoola Arka Nebulaization Followed By Bharangi Nagara Kalka Naimittika Rasayana In Tamaka shvasa vis A vis Mild to Moderate Bronchial Asthma

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/08/045122

Enrollment

100

Registered

2022-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J453- Mild persistent asthma Health Condition 2: J453- Mild persistent asthma

Interventions

Intervention1: Nebulaization Followed by Rejuvinative medicine Medicine Oral Administration: Nebulization of Bharangimoola Arka – Based on severity and response from the subject’s interval between th

Eligibility

Inclusion criteria

Inclusion criteria: Peak Expiratory Flow Rate PEFR 60 to 90 percent Conscious and well oriented Age 20 45 years Either gender Previously diagnosed cases of bronchial asthma Those patients who are ready to sign the informed consent form

Exclusion criteria

Exclusion criteria: PEFR less than 40 Patients with a history of Tuberculosis, Emphysema, Chronic airway limitation History of Cardiac involvement Other complicated respiratory diseases having any organic lesions such as a tumor or any anatomical defect in the airway Cyanosis Hypertension, Uncontrolled Diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Reduction in severity and prevetion of onset of Tamaka ShvasaTimepoint: 45 Days	—

Secondary

Measure	Time frame
NIlTimepoint: 0	—

Countries

India

Contacts

Public ContactDr Manjunatha Adiga

adiga.manjunatha@gmail.com09035715798

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026